Bate-Eya LT - Search Results

1

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.

Bate-Eya LT, den Hartog IJ, van der Ploeg I, Schild L, Koster J, Santo EE, Westerhout EM, Versteeg R, Caron HN, Molenaar JJ, Dolman ME. Bate-Eya LT, et al. Oncotarget. 2016 May 10;7(19):27946-58. doi: 10.18632/oncotarget.8547. Oncotarget. 2016. PMID: 27056887 Free PMC article.

2

DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells.

Dolman ME, van der Ploeg I, Koster J, Bate-Eya LT, Versteeg R, Caron HN, Molenaar JJ. Dolman ME, et al. Among authors: bate eya lt. PLoS One. 2015 Dec 30;10(12):e0145744. doi: 10.1371/journal.pone.0145744. eCollection 2015. PLoS One. 2015. PMID: 26716839 Free PMC article.

3

Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.

Bate-Eya LT, Gierman HJ, Ebus ME, Koster J, Caron HN, Versteeg R, Dolman MEM, Molenaar JJ. Bate-Eya LT, et al. Eur J Cancer. 2017 Apr;75:63-72. doi: 10.1016/j.ejca.2016.12.019. Epub 2017 Feb 17. Eur J Cancer. 2017. PMID: 28214660

4

High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.

Vernooij L, Bate-Eya LT, Alles LK, Lee JY, Koopmans B, Jonus HC, Schubert NA, Schild L, Lelieveld D, Egan DA, Kerstjens M, Stam RW, Koster J, Goldsmith KC, Molenaar JJ, Dolman MEM. Vernooij L, et al. Among authors: bate eya lt. Mol Cancer Ther. 2021 Jun;20(6):1161-1172. doi: 10.1158/1535-7163.MCT-20-0666. Epub 2021 Apr 13. Mol Cancer Ther. 2021. PMID: 33850004 Free PMC article.

5

Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours.

Bate-Eya LT, Ebus ME, Koster J, den Hartog IJ, Zwijnenburg DA, Schild L, van der Ploeg I, Dolman ME, Caron HN, Versteeg R, Molenaar JJ. Bate-Eya LT, et al. Eur J Cancer. 2014 Feb;50(3):628-37. doi: 10.1016/j.ejca.2013.11.015. Epub 2013 Dec 6. Eur J Cancer. 2014. PMID: 24321263

6

Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma.

Bate-Eya LT, Albayrak G, Carr SM, Shrestha A, Kanapin A, Samsonova A, La Thangue NB. Bate-Eya LT, et al. Mol Oncol. 2024 Jul 17. doi: 10.1002/1878-0261.13702. Online ahead of print. Mol Oncol. 2024. PMID: 39021294 Free article.

7

Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer.

Mamaeva V, Rosenholm JM, Bate-Eya LT, Bergman L, Peuhu E, Duchanoy A, Fortelius LE, Landor S, Toivola DM, Lindén M, Sahlgren C. Mamaeva V, et al. Among authors: bate eya lt. Mol Ther. 2011 Aug;19(8):1538-46. doi: 10.1038/mt.2011.105. Epub 2011 May 31. Mol Ther. 2011. PMID: 21629222 Free PMC article.

8

Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors.

Rosenholm JM, Peuhu E, Bate-Eya LT, Eriksson JE, Sahlgren C, Lindén M. Rosenholm JM, et al. Among authors: bate eya lt. Small. 2010 Jun 6;6(11):1234-41. doi: 10.1002/smll.200902355. Small. 2010. PMID: 20486218

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters